GoodRx (NASDAQ:GDRX) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of GoodRx (NASDAQ:GDRX) from a buy rating to a hold rating in a report issued on Saturday.

GDRX has been the subject of a number of other research reports. TD Cowen lowered their price objective on GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Mizuho decreased their price target on GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $6.00 price objective on shares of GoodRx in a research note on Monday, August 11th. UBS Group cut their price objective on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Finally, Raymond James Financial downgraded shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.52.

GoodRx Stock Performance

NASDAQ:GDRX opened at $2.85 on Friday. The firm has a 50 day simple moving average of $3.88 and a 200-day simple moving average of $4.21. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. The firm has a market cap of $967.38 million, a PE ratio of 31.67, a P/E/G ratio of 1.55 and a beta of 1.20. GoodRx has a 1-year low of $2.83 and a 1-year high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $196.03 million for the quarter, compared to analyst estimates of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The firm’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 EPS. GoodRx has set its FY 2025 guidance at EPS. On average, equities analysts expect that GoodRx will post 0.13 EPS for the current year.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total value of $95,084.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.17% of the company’s stock.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently made changes to their positions in GDRX. SBI Securities Co. Ltd. boosted its position in GoodRx by 13.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock worth $100,000 after purchasing an additional 2,748 shares during the period. Lazard Asset Management LLC raised its position in GoodRx by 43.6% in the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after purchasing an additional 5,201 shares during the period. Brevan Howard Capital Management LP lifted its stake in shares of GoodRx by 7.7% during the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after purchasing an additional 6,842 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of GoodRx by 202.3% in the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after buying an additional 7,580 shares during the period. Finally, Quarry LP acquired a new stake in shares of GoodRx in the third quarter valued at about $33,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.